Israel-based software company Medial EarlySign will work with Geisinger's innovation center to develop technologies to predict lower GI and other "high-burden" diseases.
The firm has developed a digital platform that determines whether patients meet guidelines for genetic testing, and if so, what test they should receive.
At the AGBT meeting last night, Johns Hopkins researcher Joshua Cohen said that the partners are looking to recruit 50,000 healthy individuals for the study.
The firm said that it anticipates using the funds to scale operations in the US and to continue rolling out its service in the UK.
Over several months, members of the Coalition to Improve Diagnosis identified initial obstacles they believe impede diagnostic accuracy.
The knowledgebase will facilitate the documenting of evidence and implementation of diagnostics-driven population health projects.
At the recent CVS, the two large health systems described introducing Cepheid platforms for flu testing across rural and satellite locations.
The pilot builds off the MyCode Community Research Health Initiative, for which Regeneron has been sequencing the exomes of Geisinger participants.
Patients can perform urinalysis at home using Healthy.io's smartphone-based kit, which immediately sends the data to a database for clinical interpretation.
Geisinger is hoping to help others around the country implement precision medicine, which requires significant investment in genomics expertise, as well as infrastructural and operational changes.